.jpg)
AMPHOTERICIN B FORMULATIONS FOR INHALATION BASED ON COLLAPSED MICROPARTICLES CONTAINING CARBOHYDRATES AND AMINO ACIDS
WO22129661
A formulation comprising amphotericin B based on collapsed microparticles for administration by inhalation and which additionally comprises oligosaccharides and monosaccharides, as well as amino acids, as excipients, whereby the oligosaccharides and monosaccharides are gamma-cyclodextrin and mannose, and the amino acid is leucine. The formulation can be administered using dry powder inhalers or aerosols.
ADVANTAGES Until now, other patents and scientific articles have published lipid-based antifungal pulmonary formulations and in most cases their use is intended for pulmonary administration by means of aerosols. In this case, the novelty is to manufacture collapsed microparticles with good pulmonary deposition without using lipid excipients (only based on amino acids and carbohydrates) and that can be administered in dry powder form. APPLICATIONS The application is the development of dry powder inhalers that allow both treatment and prophylaxis of pulmonary or systemic fungal infections such as aspergillosis or microbial infections caused by intracellular pathogens such as leishmaniasis or tuberculosis. With the corresponding clinical trials, a new drug for these pathologies could be marketed using the technique described for the manufacture of collapsed microparticles with an optimal size and geometry for their deposition at the pulmonary level.
The invention solves the lack of drugs available for the treatment and prophylaxis of pulmonary infections caused by fungi or intracellular pathogens such as leishmaniasis or tuberculosis.